Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Global health

WHO announces cheaper drug treatment for multidrug resistant tuberculosis

The World Health Organization (WHO) has published new recommendations that seek to speed up detection and enhance cure rates for patients with multidrug resistant tuberculosis (MDR-TB).

The WHO recommends the use of a shorter and cheaper treatment regimen, which is taken for 9–12 months, compared to the conventional and more costly treatment regimens, which are taken for 18–24 months.

“This we consider a critical step forward,” Mario Raviglione, director of WHO’s global tuberculosis (TB) programme, told reporters at a news conference on 12 May 2016.

Philippp du Cros, an infectious disease specialist with Médecins San Frontières, says WHO’s recommendations were “a positive step”, adding that countries should waste no time in putting them into practice.

The new regimen comprises seven drugs: kanamycin, moxifloxacin, prothionamide, clofazimine, pyrazinamide, high-dose isoniazid and ethambutol.

Raviglione said that studies of patients with uncomplicated MDR-TB, which is not resistant to second-line TB drugs, resulted in cure rates of 79–87% compared to 50% for the normal regimen.

The shorter drug regimen is estimated to cost less than $1,000 per patient, up to three times cheaper than the normal regimen at $1,500-$3,000.

The shorter regimen is recommended for approximately 70% of the people with MDR-TB, but it can’t be used in patients with second-line drug resistance, extrapulmonary disease and pregnancy.

To help identify patients eligible for the shorter therapy, the WHO has recommended the use of a novel DNA diagnostic test called MTBDRsI, which identifies MDR-TB strains resistant to second-line TB drugs within 24–48 hours, down from the three months at present. 

The WHO says an estimated 480,000 people developed MDR-TB in 2014 – about 5% of all TB cases – and 190,000 died from it.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201150

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Mario Raviglione, director of WHO's global tuberculosis programme

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.